Lymphocytes in Immunotherapy of Cancer by Paul KoldovskyLymphocytes in Immunotherapy of Cancer by Paul Koldovsky

Lymphocytes in Immunotherapy of Cancer

EditorPaul Koldovsky, Ursula Koldovsky, Lutwin Beck

Paperback | March 6, 1989

Pricing and Purchase Info

$159.25 online 
$167.95 list price save 5%
Earn 796 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


This book summarizes various approaches in LAK therapy. The most important question is whether synergism or antagonism to other biological response modifiers plays a role in changing the immunological specificity of LAK cells. Combined administration of LAK cells and IL-2, intraarterial and intramural administration of LAK cells, and autologous stimulation are further topics. Methods of adminstration, doses, and therapy strategies are also discussed. All articles include a section on clinical results and future prospects. Using LAK cell therapy, a method which does not directly affect the tumor but improves the defense capacity of the patient, therapeutic improvements have already been achieved. However, research indicates that, in the future, even better therapeutic results can be expected from combined approaches which include LAK cell therapy.
Title:Lymphocytes in Immunotherapy of CancerFormat:PaperbackDimensions:111 pages, 9.61 × 6.69 × 0.03 inPublished:March 6, 1989Publisher:Springer Berlin HeidelbergLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3540504575

ISBN - 13:9783540504573

Look for similar items by category:


Table of Contents

Contents: Therapy of Cancer with Interleukin-2-Activated Natural Killer Cells.- T Cell Heterogeneity and Function.- Human Lymphokine-Activated Killer Cells and Their Potential for Cancer Therapy.- In Vitro and in Vivo Induction of Lymphokine-Activated Killer Cells in Patients with Gastric Cancer and Other Solid Tumors.- Tests for Determination of Lymphocyte Activity.- Lysis of Autologous Tumor Cells by Blood Lymphocytes In Vitro Requires MHC Class I Antigen Expression.- Target Structures for Cellular Immune Mechanisms on the Surface of Epstein-Barr Virus-Infected Malignant and Nonmalignant Lymphocytes.- Human Lymphokine-Activated Killer Cells Activated with Interleukin-2 and Tumor Necrosis Factor- : Implications for Immunotherapy.- Interleukin-2 in the Treatment of Malignant Melanoma and Renal Cell Carcinoma.- Lymphokine-Activated Human Effector Cells Targeted by Monoclonal Antiganglioside Antibodies: A Preclinical Model for Immunotherapy of Human Melanoma.- Comments on the Problems of Immunotherapy with Autologous Lymphocytes.- A Clinician's Comments on Cancer Therapy with Lymphocytes.